Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The use of hematopoietic stem cells in autoimmune diseases.
Effect of vitamin D on MS activity by disease-modifying therapy class.
Novartis announces Russian regulatory approval for Gilenya®, a once-daily oral multiple sclerosis therapy and first in a new class
Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis.
BRIEF: Teva files for Copaxone-Laquinimod patent
Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis.
Development of a Bilingual MS-Specific Health Classification System: The Preference-Based Multiple Sclerosis Index.
Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism.
Recent insights into the mechanism of action of glatiramer acetate.
Paucity and Inconsistency: A Systematic Review and Critique of Budget Impact Analyses of Disease-Modifying Therapies for Multiple Sclerosis in the UK and the Implications for Policy in the UK.
Development of Guillain-Barré syndrome in a patient with multiple sclerosis during treatment with glatiramer acetate.
Internal Jugular Vein Cross-Sectional Area and Cerebrospinal Fluid Pulsatility in the Aqueduct of Sylvius: A Comparative Study between Healthy Subjects and Multiple Sclerosis Patients.
Neuromyelitis optica spectrum disorder (NMOSD): A new concept.
Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis.
Clarity Extension Study
Genzyme’s once-daily, oral AUBAGIO® (teriflunomide) approved in Argentina for the treatment of relapsing multiple sclerosis
Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis.
Fatigue and Comorbidities in Multiple Sclerosis.
Plasma ubiquitin?proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b.
Regulation of dimethyl-fumarate toxicity by proteasome inhibitors.
Decreased systemic IL-7 and soluble IL-7Rα in multiple sclerosis patients.
Optical Coherence Tomography in Multiple Sclerosis.
Brain Cholesterol Metabolism and Its Defects: Linkage to Neurodegenerative Diseases and Synaptic Dysfunction.
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Characterization and quantitation of aggregates and particles in interferon-β products: Potential links between product quality attributes and immunogenicity.

Pages